there have been no reports of organ damage or severe reactions directly linked to NAD+ in clinical studies
BPC-157 is not FDA-approved and is not a licensed drug in the US, UK, EU, or Australia
Cardiovascular Emerging Evidence Evidence Rating: Emerging (Preliminary animal data) Cardiovascular applications are less studied but intriguing: Cardiac protection Arrhythmia prevention Blood vessel healing Collateral vessel formation Regulatory Status FDA Classification BPC-157 is not approved by the FDA for any medical use in humans
Supplements and Nutrition Collagen peptides provide raw materials for tissue repair
Human data remain limited, but animal research has shown consistent healing-related effects
In LUKE Health, this is enforced at the database level with dual-layer triggers it cannot be bypassed through the UI, API, or any other channel